Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant

被引：10

作者：

Kovalenko, Angelina O. ^{[1
]}

Ryabchevskaya, Ekaterina M. ^{[1
]}

Evtushenko, Ekaterina A. ^{[1
]}

Manukhova, Tatiana I. ^{[1
]}

Kondakova, Olga A. ^{[1
]}

Ivanov, Peter A. ^{[1
]}

Arkhipenko, Marina V. ^{[1
]}

Gushchin, Vladimir A. ^{[1
,2
]}

Nikitin, Nikolai A. ^{[1
]}

Karpova, Olga V. ^{[1
]}

机构：

[1] Lomonosov Moscow State Univ, Fac Biol, Dept Virol, Moscow, Russia

[2] Minist Hlth Russian Federat, NF Gamaleya Natl Res Ctr Epidemiol & Microbiol, Moscow, Russia

来源：

FRONTIERS IN MICROBIOLOGY | 2022年 / 13卷

基金：

俄罗斯基础研究基金会;

关键词：

coronaviruses; vaccine candidate; plant virus; adjuvant; tobacco mosaic virus; structurally modified plant virus; RECEPTOR-BINDING DOMAIN; TOBACCO-MOSAIC-VIRUS; SARS-COV-2; SPIKE; SPHERICAL-PARTICLES; SARS-COV; PROTEIN; MUTATIONS; INFECTION; EPITOPES; VIRIONS;

D O I：

10.3389/fmicb.2022.845316

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A recombinant vaccine candidate has been developed based on the major coronaviruses' antigen (S protein) fragments and a novel adjuvant-spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2 protein subunit were chosen for the design of recombinant coronavirus antigens. The set of three antigens (Co1, CoF, and PE) was developed and used to create a vaccine candidate composed of antigens and SPs (SPs + 3AG). Recognition of SPs + 3AG compositions by commercially available antibodies against spike proteins of SARS-CoV and SARS-CoV-2 was confirmed. The immunogenicity testing of these compositions in a mouse model showed that SPs improved immune response to the CoF and PE antigens. Total IgG titers against both proteins were 9-16 times higher than those to SPs. Neutralizing activity against SARS-CoV-2 in serum samples collected from hamsters immunized with the SPs + 3AG was demonstrated.

引用

页数：15

共 50 条

[21] Spike D614G-A Candidate Vaccine Antigen Against Covid-19
Koenig, Paul-Albert
Schmidt, Florian I.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (24): : 2349 - 2351
[22] Covid-19: Third candidate vaccine will be tested in UK
Torjesen, Ingrid
BMJ-BRITISH MEDICAL JOURNAL, 2020, 371 : m4451
[23] Clinical Equipoise in COVID-19 Vaccine Candidate Trials
Dal-Re, Rafael
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (09): : 1249 - 1250
[24] Adjuvantation helps to optimise COVID-19 vaccine candidate
Li, Jing-Xin
Zhu, Feng-Cai
LANCET INFECTIOUS DISEASES, 2021, 21 (07): : 891 - 893
[25] A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles
Karan, Sweta
Opdensteinen, Patrick
Ma, Yifeng
De Oliveira, Jessica Fernanda Affonso
Steinmetz, Nicole F.
VACCINE, 2025, 53
[26] Vaccine against Covid-19, a race against time
Guerriaud, Mathieu
ACTUALITES PHARMACEUTIQUES, 2021, 60 (603): : 1 - 1
[27] BCG Vaccine Not Effective Against COVID-19
Harris, Emily
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (20): : 1730 - 1730
[28] Offline: Preparing for a vaccine against COVID-19
Horton, Richard
LANCET, 2020, 396 (10246): : 226 - 226
[29] Challenges in the Development of a Vaccine Against COVID-19
Chen, Wei
Zhu, Feng-Cai
ENGINEERING, 2020, 6 (10) : 1067 - 1069
[30] Heterologous vaccine regimens against COVID-19
Duarte-Salles, Talita
Prieto-Alhambra, Daniel
LANCET, 2021, 398 (10295): : 94 - 95

← 1 2 3 4 5 →